Skip to Main Content

Khizroev, Sakhrat

Title: Professor

Office: EC 3955

Phone: 305-348-3724

Email: khizroev@fiu.edu

Department(s): Cellular Biology and Pharmacology

His research focus at the Department of Cellular Biology and Pharmacology is at the intersection of nanotechnology and medicine. His team has developed a class of multiferroic nanoparticles known as magnetoelectric nanoparticles to treat cancer, HIV/AIDS, neurodegenerative diseases, and others.  Their research to use nanoparticles to wirelessly control the central nervous system for pinpoint treatment at the single-neuron level and reverse engineering the brain was listed among the top 100 science stories of year 2015 by Discover Magazine. A Fellow of National Academy of Inventors, Khizroev holds over 33 US Patents. He has authored over 135 peer-reviewed papers and given over 100 talks including many invited talks and tutorials at international conferences in the field of nanotechnology. He received his Ph.D. from Carnegie Mellon University in 1999, his B.S. and M.S. in Physics from Moscow Institute of Physics and Technology (MIPT aka PhysTech) in 1992 and 1994, respectively. Prior to joining academia, he spent one year as a Doctoral Fellow with IBM Almaden Research Center and 4 years as a Research Staff Member with Seagate Research.

Research Interests:

Function of relaxin peptides and their GPCRs is the center of the research activities in Dr. Agoulnik laboratory. Using transgenic mouse models, cell biology approaches, genomics and proteomic techniques we study the effects of different hormonal stimuli in ontogenesis and function of various organs. The special emphasis of our research is the identification and characterization of small molecule modulators of relaxins’ GPCR. Currently the following projects are underway:

  1. "Small molecule antagonists of relaxin receptor" (NCI, 1U01CA177711, PI: AI Agoulnik). We have shown that the inhibition of relaxin hormone signaling suppresses prostate cancer progression. In collaboration with NIH/NCATS researchers we will perform a high throughput screening of a large library of small molecules to isolate chemical compounds that disrupt relaxin signaling and can be potentially used as the anti-cancer drugs.

  2. "Relaxin receptor agonists for treatment of liver fibrosis”(NIDDK, 1R01DK110167, PI: AI Agoulnik). The goal of this project is to study the effects of relaxin receptor agonists as therapeutic agents in liver fibrosis. This study is a collaboration with scientists from Wake Forest Institute for Regenerative Medicine and from NCATS.

  3. "Small molecule agonists of insulin-like3 receptor for treatment of osteoporosis" (NIAMS, 1R01AR070093, PI: AI Agoulnik). The goal of this project is to identify small molecule agonists of Insulin-like3 hormone receptor for treatment of osteoporosis and reproductive abnormalities.

  4. "Small molecule relaxin receptor agonists in treatment of uterine fibroids" (Bayer Pharma Aktiengesellschaft, Grants4Targets 2016-08-1711, PI: AI Agoulnik). The goal of the proposal to study the effects of relaxin signaling on development of uterine leiomyomas.

Several other projects related to understanding mechanisms of hormonal stimulation and therapeutic testing of small molecule compounds are in progress.

Recent Publications:

  1. A. Hadjikhani, A. Rodzinski, P. Wang, A. Nagesetti, R. Guduru, P. Liang, C. Runowicz, S. Shahbazmohamadi, and S. Khizroev,”Biodistribution and clearance of magnetoelectric nanoparticles for nanomedical applications using energy dispersive spectroscopy,” Nanomedicine (London) 12 (15); 1801-1822 (2017)
  2. A. Nagesetti, A. Rodzinski, E. Stimphil, T. Stewart, C. Khanal, P. Wang, R. Guduru, P. Liang, I. Agoulnik, J. Horstmyer, and S. Khizroev, “Multiferroic coreshell magnetoelectric nanoparticles as NMR sensitive nanoprobes for cancer cell detection,” Scientific Reports 7, 1610 (2017)
  3. E. Stimphil, A. Nagasetti, R. Guduru, T. Stewart, A. Rodzinski, P. Liang, and S. Khizroev, “Physics considerations in targeted anticancer drug delivery by magnetoelectric nanoparticles,” Appl. Phys. Rev., 4 (2), 021101 (2017)        
  4. A. Rodzinski, R. Guduru, P. Liang, A. Hadjikhani, T. Stewart, E. Stimphil, C. Runowicz, R. Cote, N. Altman, R. Datar, and S. Khizroev, “Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles,” Scientific Reports 6, 20867 (2016); Cancer Research 76 (14 S), 2204 (2016)
  5. R. Guduru, P. Liang, J. Hong, A. Rodzinski, A. Hadjikhani, J. Horstmyer, E. Levister, and S. Khizroev, “Magnetoelectric “spin” on stimulating the brain,” Nanomedicine (London) 10 (13), 2051-2061 (2015)
  6. R. Guduru and S. Khizroev, “Magnetic-field-controlled release of paclitaxel drug from functionalized magneto-electric nanoparticles,” Particle and Particle Systems Characterization 31 (5), 605-611 (2014)
  7. J. Hong, E. Bekyarova, W. de Heer, R. Haddon, and S. Khizroev, “Chemically engineered graphene-based 2-D organic molecular magnet,” ACS Nano 7(11), Article ASAP 10011-10022  (2013)
  8. R. Guduru, P. Liang, C. Runowicz, M. Nair, V. Alturi, and S. Khizroev, “Magnetoelectric nanoparticles to enable field-controlled high-specificity drug delivery to eradicate ovarian cancer cells,”  Scientific Reports 3, 2953 (2013)
  9. M. Nair, R. Guduru, P. Liang, J. Hong, V. Sagar, and S. Khizroev, “Externally-controlled on-demand release of anti-HIV drug AZTTP using magneto-electric nanoparticles as carriers,”  Nature Communications 4, 1707 (2013)
  10. K. Yue, R. Guduru, J. Hong, P. Liang, M. Nair, and S. Khizroev, “Magneto-electric nanoparticles for non-invasive brain stimulation,” PLoS ONE  7(9), e44040 (2012)